Skip to main content

Agilent, Anderson Forschung to Collaborate on Protein Assays

NEW YORK (GenomeWeb News) – Agilent Technologies and Anderson Forschung Group have agreed to collaborate on the development of quantitative peptide assays for protein biomarker discovery and validation, the partners said today.

Under the agreement, Agilent and AFG will combine AFG's peptide targeting technology, called stable isotope standards and capture by anti-peptide antibodies (SISCAPA), with Agilent's 1200 HPLC-Chip and its 6400 Series triple quadrupole mass spectrometers. The companies said that the combined technologies will be used to develop methods for measuring peptides in digests of complex samples such as plasma.

"One of the greatest challenges to delivering useful knowledge using the protein biomarker discovery paradigm is achieving effective, reproducible and highly sensitive peptide quantitation," Agilent's VP and GM of its Biological Systems Division, Gustavo Salem, said in a statement.

The SISCAPA method uses antibody-coated magnetic beads and a magnetic bead trap device to target peptides, which are measured using an LC-MS/MS system.

"SISCAPA assays for candidate biomarkers can benefit substantially from the reproducibility and sensitivity of Agilent's platform, and we look forward to optimizing this combination," AFG CEO Leigh Anderson said in a statement.

Financial terms of the agreement were not released.

The Scan

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.